IP Library Granted Patent US 11,426,369
Granted Patent B2
US 11,426,369 · App. 17/556,904 · Granted Aug 30, 2022

Compositions comprising ephedrine or an ephedrine salt and methods of making and using same

Inventor: Shahid Ahmed (Lincolnshire, IL)
Assignee: Nexus Pharmaceuticals, Inc.
A61K31/137A61K9/0019
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,426,369
App. No.
17/556,904
Granted
Aug 30, 2022
Kind
B2
Abstract

The present disclosure provides compositions comprising ephedrine sulfate ready for immediate use in a clinical setting, and methods of making and using same.

Claims (16)

1. A method of making a shelf-stable, ready-to-use ephedrine sulfate composition, the method comprising:

combining ephedrine sulfate, sodium chloride or dextrose, and water to form a batch solution comprising an initial ephedrine sulfate level of 5 mg/mL, 9 mg/mL sodium chloride or 5% dextrose, and no preservative;

optionally contacting the batch solution with an acid or a base to obtain an initial pH level of the solution of 4.5 to 7;

filtering the batch solution through a membrane filter to obtain a filtered batch solution;

sanitizing one or more containers;

placing not more than 20 mL of the filtered batch solution into one of the one or more sanitized containers to obtain one or more filled containers;

sealing each filled container to obtain sealed containers including a shelf-stable, ready-to-use ephedrine sulfate composition; and

maintaining a pH level of the shelf-stable, ready-to-use ephedrine sulfate composition in the sealed containers that is within 0.5 pH units of the initial pH level during storage at 25° C. and 60% relative humidity for at least 12 months or during storage at 40° C. and 75% relative humidity for at least 6 months.

2. The method of claim 1 , wherein the shelf-stable, ready-to-use ephedrine sulfate composition has, after the step of maintaining, a bacterial endotoxin level of not more than 7 EU/mg.

3. The method of claim 1 , wherein the shelf-stable, ready-to-use ephedrine sulfate composition has, after the step of maintaining, an ephedrine level within 5% of the initial ephedrine sulfate level.

4. The method of claim 1 , wherein the shelf-stable, ready-to-use ephedrine sulfate composition has, after the step of maintaining, a level of (+)-1S,2R-ephedrine of not more than 0.5%.

5. The method of claim 1 , wherein the shelf-stable, ready-to-use ephedrine sulfate composition has, after the step of maintaining, a level of total impurities of not more than 0.75%.

6. The method of claim 1 , wherein the shelf-stable, ready-to-use ephedrine sulfate composition has, after the step of maintaining, a level of any one unknown individual impurity of not more than 0.2%.

7. The method of claim 1 , wherein the shelf-stable, ready-to-use ephedrine sulfate composition has, after the step of maintaining, not more than 6000 particles greater than or equal to 10 μm in size per container.

8. The method of claim 1 , wherein the shelf-stable, ready-to-use ephedrine sulfate composition has, after the step of maintaining, not more than 600 particles greater than or equal to 25 μm in size per container.

9. The method of claim 1 further comprising a step of sterilizing the solution before the step of maintaining.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jun 3, 2024
From: SAGENT GROUP, LLC
To: NEXUS PHARMACEUTICALS, LLC; NEXPHARM PARENT HOLDCO, LLC; ISOPRO HOLDINGS, LLC
Reel/Frame 067600/0837 →
CHANGE OF NAME Recorded May 26, 2023
From: NEXUS PHARMACEUTICALS II, LLC
To: NEXUS PHARMACEUTICALS, LLC
Reel/Frame 063789/0675 →
STATUTORY CONVERSION Recorded May 24, 2023
From: NEXUS PHARMACEUTICALS, INC.
To: NEXUS PHARMACEUTICALS II, LLC
Reel/Frame 063752/0975 →
SECURITY INTEREST Recorded May 8, 2023
From: NEXUS PHARMACEUTICALS, LLC; NEXPHARM PARENT HOLDCO, LLC; ISOPRO HOLDINGS, LLC
To: SAGENT GROUP, LLC
Reel/Frame 063568/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2021
From: AHMED, SHAHID
To: NEXUS PHARMACEUTICALS, INC.
Reel/Frame 058442/0350 →
Continuity (4)
Continuation 17381770 · Jul 21, 2021
Continuation 16876020 · May 16, 2020
Provisional Application 62849125 · May 16, 2019
Related Publication 20220110892A1 · Apr 14, 2022